What question did this study set out to answer?

To evaluate the motor behavioral effects of coadministering the selective dopamine D1 agonist SKF 81297 and the D2 agonist LY 171555 in a primate model of Parkinson's disease.

January 1, 1994Movement Disorders

The dopamine D₁ agonist SKF 81297 and the dopamine D₂ agonist LY 171555 act synergistically to stimulate motor behavior of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐lesioned parkinsonian rhesus monkeys

View Full Paper

Ask AI

Bookmark

To evaluate the motor behavioral effects of coadministering the selective dopamine D1 agonist SKF 81297 and the D2 agonist LY 171555 in a primate model of Parkinson's disease.
Administered SKF 81297 and LY 171555, alone and in combination, to unilaterally MPTP-lesioned rhesus monkeys.
Tested behaviorally active doses (0.3 mg/kg SKF 81297 and 0.01 mg/kg LY 171555) as well as subthreshold, inactive doses (0.03 mg/kg SKF 81297 and 0.003 mg/kg LY 171555) to measure changes in motor stimulation duration and magnitude.
Coadministration of active doses of SKF 81297 and LY 171555 prolonged the duration of motor stimulation compared to either drug given individually.
Combined administration of subthreshold doses of both compounds elicited significant stimulation of motor behavior, whereas neither dose was active on its own.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Experimental study demonstrates enhanced motor stimulation with combined D1 and D2 agonists in parkinsonian monkeys, indicating simultaneous receptor activation improves Parkinson's therapy.

Cite This Study

Vermeulen et al. (1994) studied this question.

synapsesocial.com/papers/6a6fd1f8e5469ee92be0a661 https://doi.org/10.1002/mds.870090613

View Full Paper

Ask AI

Bookmark

Implication

Experimental study demonstrates enhanced motor stimulation with combined D1 and D2 agonists in parkinsonian monkeys, indicating simultaneous receptor activation improves Parkinson's therapy.

The dopamine D₁ agonist SKF 81297 and the dopamine D₂ agonist LY 171555 act synergistically to stimulate motor behavior of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐lesioned parkinsonian rhesus monkeys

Key Points

Discussion

Implication

Cite This Study

The dopamine D₁ agonist SKF 81297 and the dopamine D₂ agonist LY 171555 act synergistically to stimulate motor behavior of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐lesioned parkinsonian rhesus monkeys

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider